Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578732 · ClinicalTrials.gov registry record · Phase 2
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
A Phase 2 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02578732 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 28 participants.
The verdict
NCT02578732, a Phase 2 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10 cycles of therapy. Investigators therefore will evaluate FOLFOX-A in a phase II study for patient with locally advanced pancreatic cancer.
Interventions
- DRUG FOLFOXA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-07-12 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02578732
The ClinicalTrials.gov registry entry for NCT02578732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FOLFOXA is the first listed.
NCT02578732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02578732 about?
NCT02578732 is a clinical study titled "FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial". Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10 cycles of therapy. Investigators therefore will evaluate FOLFOX-A in a ph...
What is the current status of trial NCT02578732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2016-07-12. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT02578732?
The interventions under investigation include: FOLFOXA (DRUG).
Who is sponsoring clinical trial NCT02578732?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.